Daniela Ramirez de Jesús
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daniela Ramirez de Jesús has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aloha Meave-González
Instituto Nacional de Cardiología “Ignacio Chávez
1 shared publication - Blanca Rebeca Ibarra-Ibarra
Cardiogenetics Clinic, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
1 shared publication - Daniel Vera Ibarra
Cardiomyopathy Clinic, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
1 shared publication - Dante Palacios Gutierrez
Cardiomyopathy Clinic, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
1 shared publication - Edith Liliana Posada Martínez
Department of Echocardiography, Instituto Nacional de Cardiología Ignacio Chavez, Mexico City, Mexico
1 shared publication - Enrique Alexander Berrios Barcenas
Cardiomyopathy Clinic, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
1 shared publication
Latest Publications
- Open Access
- 25 July 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Screening of fabry disease in patients with left ventricular hypertrophy: a single-center study in Mexico
Background: Fabry disease (FD) is an X-linked sphingolipidosis caused by enzyme α-Galactosidase A (α-Gal A) deficiency due to pathogenic variants in GLA gene. Progressive glycosphingolipid accumulation leads to subsequent myocyte injury, which frequently induces concentric remodeling and manifests as left ventricular hypertrophy (LVH). This study aims to describe the prevalence of FD in patients with LVH diagnosis in a Mexican population. Methods: Consecutive and unrelated patients with echocardiographic evidence of left ventricular hypertrophy (LVH) without known cause were screened for FD in a Mexican cardiology referral center. Globotriaosylsphingosine (lyso-Gb3) levels and α-Gal A activity were measured using the dry blood spot method in all male individuals. Patients with positive dried blood spot testing and female patients were confirmed by single-gene sequencing. Results: 205 patients with LVH (48.5 ± 18.7 years) were included. Of these, 53% were male, 60% were in NYHA functional class I, and 43% were asymptomatic. Dyspnea was the most frequently reported symptom, occurring in 26% of cases. Among study participants, three women were diagnosed with FD (1.5%). GLA gene sequencing revealed two pathogenic variants, NM_000169.3( GLA ):c.559 A > G (p.Met187Val) and NM_000169.3( GLA ):c.679 C > T (p.Arg227Ter), and a variant of unknown significance (VUS) reclassificated to a likely pathogenic variant NM_000169.3( GLA ):c.122 C > G (p.Thr41Ser). Cascade screening identified three additional women with FD. Conclusion: These results emphasize the need for genetic screening for FD in female individuals with LVH. Further studies are needed to understand genotype-phenotype correlations in females with genetic variants in the GLA gene, particularly those with VUS and novel variants, as they pose challenges for diagnosis and treatment.
- 25 July 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessScreening of fabry disease in patients with left ventricular hypertrophy: a single-center study in Mexico
Background: Fabry disease (FD) is an X-linked sphingolipidosis caused by enzyme α-Galactosidase A (α-Gal A) deficiency due to pathogenic variants in GLA gene. Progressive glycosphingolipid accumulation leads to subsequent myocyte injury, which frequently induces concentric remodeling and manifests as left ventricular hypertrophy (LVH). This study aims to describe the prevalence of FD in patients with LVH diagnosis in a Mexican population. Methods: Consecutive and unrelated patients with echocardiographic evidence of left ventricular hypertrophy (LVH) without known cause were screened for FD in a Mexican cardiology referral center. Globotriaosylsphingosine (lyso-Gb3) levels and α-Gal A activity were measured using the dry blood spot method in all male individuals. Patients with positive dried blood spot testing and female patients were confirmed by single-gene sequencing. Results: 205 patients with LVH (48.5 ± 18.7 years) were included. Of these, 53% were male, 60% were in NYHA functional class I, and 43% were asymptomatic. Dyspnea was the most frequently reported symptom, occurring in 26% of cases. Among study participants, three women were diagnosed with FD (1.5%). GLA gene sequencing revealed two pathogenic variants, NM_000169.3( GLA ):c.559 A > G (p.Met187Val) and NM_000169.3( GLA ):c.679 C > T (p.Arg227Ter), and a variant of unknown significance (VUS) reclassificated to a likely pathogenic variant NM_000169.3( GLA ):c.122 C > G (p.Thr41Ser). Cascade screening identified three additional women with FD. Conclusion: These results emphasize the need for genetic screening for FD in female individuals with LVH. Further studies are needed to understand genotype-phenotype correlations in females with genetic variants in the GLA gene, particularly those with VUS and novel variants, as they pose challenges for diagnosis and treatment.